| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,074 | 0,158 | 16:26 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | Probiotix Health PLC - Final Results and Investor Presentation | 1 | RNS | ||
| 16.03. | Probiotix Health PLC - Notice of Results and Investor Presentation | - | RNS | ||
| 17.02. | Probiotix Health PLC - PDMR Shareholding | - | RNS | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 16.02. | ProBiotix says shares hit by "mistaken assumptions" of link to SkinBio | 2 | Alliance News | ||
| 16.02. | Probiotix Health PLC - Statement re Share Price Movement | 2 | RNS | ||
| 04.02. | Probiotix Health PLC - Director/PDMR Shareholding | 2 | RNS | ||
| 21.01. | ProBiotix Health says annual gross profit jumps as sales increase 45% | 3 | Alliance News | ||
| 21.01. | Probiotix Health PLC - Trading Update | 1 | RNS | ||
| 03.11.25 | Probiotix Health PLC - Move from Access to Apex Segment of Aquis | 1 | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,027 | -2,90 % | Medigene: Zurückziehung - 18.11.2025 | ||
| CO.DON | 0,015 | 0,00 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| TME PHARMA | 0,070 | -2,93 % | TME Pharma NV: TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications | TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET - TME Pharma... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,350 | -2,23 % | Senf-Power als Wachstums-Turbo! Agrar-Giganten gegen grüne Rebellen: Das Rendite-Potenzial von Bayer, KWS Saat und MustGrow Biologics im Check | Die Weltbevölkerung wächst unaufhörlich, während die verfügbare Ackerfläche pro Kopf schrumpft. In diesem dramatischen Umfeld bewegen sich Unternehmen, die an Lösungen arbeiten, um unsere Grundversorgung... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,083 | 0,00 % | Replenish Nutrients Expands Revolving Credit Facilities by $1.95 Million to Support Beiseker Scale-Up and Licensing Growth | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,015 | +1.750 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,025 | -35,90 % | Biovaxys Technology Corp (2): Biovaxys Technology has no material changes | ||
| TELO GENOMICS | 0,032 | +6,67 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy | - Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing... ► Artikel lesen | |
| MEDMIRA | 0,030 | 0,00 % | MedMira, Inc.: MedMira Reports Second Quarter Results FY2025 | HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026.Corporate updateIn Q2 FY2026, the Company... ► Artikel lesen | |
| GENETIC TECHNOLOGIES | 0,034 | -100,00 % | GENETIC TECHNOLOGIES LIMITED: Long Term Suspended Entities | ||
| BIOPHYTIS | 0,027 | -27,64 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen |